Complement System

补体系统 (Complement System) 由 30 多种血清和细胞表面成分组成,作为先天和后天免疫系统的一部分,参与识别和消除病原体。一旦补体系统被激活,就会发生一系列涉及蛋白水解和组装的反应,导致第三个补体成分 (C3) 裂解。C3 裂解之前的级联称为激活途径。有三种激活途径:经典途径、凝集素途径和替代途径。

补体级联是一把双刃剑,通过促进吞噬作用和炎症来防止细菌和病毒入侵。从病理学上讲,如果补体得不到充分控制,可能会对血管(血管炎)、肾基底膜和附着的内皮细胞和上皮细胞(肾炎)、关节滑膜(关节炎)和红细胞(溶血)造成严重损害。

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

共 133种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
3-O-(2'E,4'Z-Decadienoyl)ingenol
3-O-(2'E,4'Z- 癸二烯酰基) 巨大戟二萜醇

3-O-(2'E,4'Z-Decadienoyl)ingenol 是一种具有显著抗补体活性的天然二萜,其 IC50 为 89.5 μM。

84680-59-1
Inhibitor
3-O-(2'E,4'Z- 癸二烯酰基) 巨大戟二萜醇
3-Phenoxybenzaldehyde
m-Phenoxybenzaldehyde

3-Phenoxybenzaldehyde 具有微弱的补体经典途径抑制作用和溶血活性。

39515-51-0
Inhibitor
99.21%
3-Phenoxybenzaldehyde
Agazisiran

Agazisiran 是一种 siRNA,可作为补体因子 B 的合成抑制剂。

2985646-78-2
Inhibitor
Agazisiran
Agazisiran sodium

Agazisiran sodium 是一种 siRNA,可作为补体因子 B 的合成抑制剂。

Inhibitor
Agazisiran sodium
Agazisiran sodium scrambled negative control

Agazisiran sodium scrambled negative control 是 Agazisiran sodium 的乱序阴性对照。

Inhibitor
Agazisiran sodium scrambled negative control
AKIR001

AKIR001 是一种靶向 CD44v6 的高亲和力人源化 IgG1 抗体,其 FcγR 结合域携带 LALA 抑制突变,可减少与 FcγR 和 C1q 的相互作用,从而降低组织相互作用并限制补体依赖性细胞毒性 (CDC) 和抗体依赖性细胞介导的细胞毒性 (ADCC) 的风险,而 [177Lu] 标记的 AKIR001(即 [177Lu]Lu-AKIR001)被发现对表皮样癌具有抗肿瘤活性。

Inhibitor
AKIR001
AMY-101
Cp40

AMY-101 (Cp40) 是一种补体 C3 肽类抑制剂(KD = 0.5 nM),可抑制非人类灵长类动物自然发生的牙周炎,并在 COVID-19 重症肺炎合并全身超炎症模型中展现出良好的抗炎活性。

1427001-89-5
Inhibitor
99.86%
AMY-101
AMY-101 acetate
Cp40 acetate

AMY-101 acetate (Cp40 acetate) 是一种补体 C3 肽类抑制剂(KD = 0.5 nM),可抑制非人类灵长类动物自然发生的牙周炎,并在 COVID-19 重症肺炎合并全身超炎症模型中表现出良好的抗炎活性。

Inhibitor
99.93%
AMY-101 acetate
AMY-101 TFA
Cp40 TFA

AMY-101 TFA (Cp40 TFA) 是一种补体 C3 肽类抑制剂(KD = 0.5 nM),可抑制非人类灵长类动物自然发生的牙周炎,并在 COVID-19 重症肺炎合并全身超炎症模型中表现出良好的抗炎活性。

1789738-04-0
Inhibitor
99.92%
AMY-101 TFA
Anti-CD55 Antibody

Anti-CD55 Antibody 是一种抗 CD55 抗体,推荐的同型对照为 Human IgG1 kappa, Isotype Control (MS-E04981)。

Inhibitor
99.76%
Anti-CD55 Antibody
Anti-CD88/C5AR1 Antibody (G2_anti-C5aR)

Anti-CD88/C5AR1 Antibody (G2_anti-C5aR) 是一种靶向 C5AR1 的人类单克隆抗体 (mAb)。

Inhibitor
Anti-CD88/C5AR1 Antibody (G2_anti-C5aR)
Anti-Complement Factor P/Properdin Antibody

Anti-Complement Factor P/Properdin Antibody 是一种靶向 Complement Factor P/Properdin 的 CHO 表达人源抗体,带有 huIgG1 型重链和 huκ 型轻链,预测分子量 (MW) 为 150 kDa,其同型对照可参考 Human IgG1 kappa, Isotype Control (MS-E04981)。

Inhibitor
98.04%
Anti-Complement Factor P/Properdin Antibody

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础